Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors
作者:Anand Balupuri、Dae-Yon Lee、Myeong Hwi Lee、Sangeun Chae、Eunmi Jung、Yunki Kim、Jeonghee Ryu、Nam Sook Kang
DOI:10.1016/j.bmcl.2017.07.022
日期:2017.9
displayed higher potency (IC50 = 14.99 nM) than the first clinical ATX inhibitor, GLPG1690 (IC50 = 242.00 nM) in the human plasma assay. Molecular docking studies were carried out to explore the binding pattern of newly synthesized compounds within active site of ATX. Docking studies suggested the putative binding mode of the novel compounds. Good ATX inhibitory activity of 21 was attributed to the hydrogen
紫杉醇-糖原酸(ATX-LPA)信号通路涉及多种人类疾病,例如癌症,自身免疫性疾病,炎性疾病,神经退行性疾病和纤维化疾病。在此,设计并合成了一系列基于4-苯基噻唑的化合物。使用FS-3和人血浆分析法评估化合物的ATX抑制活性。在FS-3分析中,化合物20和21在低纳摩尔浓度(分别为IC 50 = 2.99和2.19 nM)下显着抑制了ATX 。发现21的抑制活性比PF-8380(IC 50 = 2.80 nM)略好,PF-8380是迄今报道的最有效的ATX抑制剂之一。此外21 在人血浆检测中显示出 比第一种临床ATX抑制剂GLPG1690(IC 50 = 242.00 nM)更高的效价(IC 50 = 14.99 nM)。进行了分子对接研究以探索新合成的化合物在ATX活性位点内的结合模式。对接研究表明了新型化合物的推定结合模式。良好的ATX抑制活性为21,这归因于与Asn230,Trp